- |||||||||| prednisone / generics, furosemide / generics, epirubicin / generics
Journal: Hypercalcemia of Malignancy in a Dog Diagnosed With Cholangiocellular Carcinoma. (Pubmed Central) - Jul 12, 2019 Chemotherapy with intravenous epirubicin was initiated based on the cytological diagnosis...Postmortem examination confirmed a cholangiocellular carcinoma. To our knowledge, this is the first report of malignant hypercalcemia associated with cholangiocellular carcinoma in a dog.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion date, Trial primary completion date: Reduced Chemotherapy in Low Risk DLBCL (clinicaltrials.gov) - Jul 8, 2019 P4, N=290, Recruiting, Not yet recruiting --> Recruiting Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Apr 2019 --> Apr 2020
- |||||||||| doxorubicin hydrochloride / generics
Journal, IO Biomarker: Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity. (Pubmed Central) - Jun 28, 2019 Moreover, enforced expression of Sirt1 alleviated Dox-induced apoptosis of H9c2 cells, with suppressing levels of p66shc, Bax, the activated caspase-3 and miR-34a-5p, and enhancing Bcl-2 expression. Therefore, miR-34a-5p enhances cardiomyocyte apoptosis by targeting Sirt1, activation of miR-34a-5p/Sirt1/p66shc pathway contributes to Dox-induced cardiotoxicity, and blockage of this pathway represents a potential cardioprotective effect against anthracyclines.
- |||||||||| Trial completion, Metastases: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Jun 19, 2019
P2/3, N=716, Completed, Toxicity was high, but infrequently led to hospitalisation or discontinuation of treatment. Active, not recruiting --> Completed
- |||||||||| epirubicin / generics
Journal: Gradiently degraded electrospun polyester scaffolds with cytostatic for urothelial carcinoma therapy. (Pubmed Central) - Jun 17, 2019 ...The purpose of this study was to reveal the possibility of the controlled delivery of epirubicin (EPI) via gradiently degraded electrospun poly(ε-caprolactone) (PCL)/poly(lactide-co-glycolide) (PLGA) scaffolds to evaluate their antitumor activity against UTUC...The EPI-loaded PCL/PLGA scaffolds showed excellent antitumor activities both in vitro and in vivo without apparent systemic toxicity. Overall, the gradiently-degraded EPI-loaded electrospun polyester scaffolds are potential ureteral stent tubes for the local inhibition of the recurrence of UTUC, where the continued release of EPI can prevent the subsequent proliferation of residual tumor cells, and the gradient degradation is consistent with the repair of the ureter.
- |||||||||| epirubicin / generics
Journal: ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. (Pubmed Central) - Jun 15, 2019 ...At the molecular level, ectopic expression of ZEB1 impaired the responsiveness of breast cancer cells to genotoxic drug treatment, such as epirubicin (EPI)...Using a nude mouse xenograft model, we further confirmed that ectopic expression of ZEB1 decreased breast cancer responsiveness to EPI treatment in vivo. Collectively, our findings suggest that ZEB1 is a crucial determinant of chemotherapeutic resistance in breast cancer.
- |||||||||| Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
Trial completion date, Trial primary completion date: TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) - Jun 7, 2019 P3, N=500, Active, not recruiting, However, grades 2-3 alopecia was seen less often with prolonged post-infusion scalp cooling. Trial completion date: Apr 2020 --> Oct 2019 | Trial primary completion date: Apr 2019 --> Sep 2019
- |||||||||| epirubicin micelle formulation (NC-6300) / NanoCarrier
Journal: Function of Epirubicin-Conjugated Polymeric Micelles in Sonodynamic Therapy. (Pubmed Central) - Jun 6, 2019 In conclusion, drug-conjugated micellar nanoparticles are more desirable for SDT because of accelerated ROS production and drug protection from ROS. Furthermore, a combination of NC-6300 and TP-HIFU is useful for minimally invasive cancer therapy with cooperative effects of HIFU-derived features, antitumor activity of EPI, and increased ROS generation to cause damage to cancer cells.
- |||||||||| Clinical, P2/3 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (Pubmed Central) - Jun 5, 2019
P2/3 The targeted drug delivery through external magnet-attraction using EPI-loaded MMSNs resulted in high tumor cell uptake, which leads to elimination of cancer cells effectively. In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared with perioperative ECF/ECX.
- |||||||||| paclitaxel / generics, cyclophosphamide intravenous / generics
Clinical, Journal: Primary breast cancer in a patient with Wilson disease: A case report. (Pubmed Central) - Jun 5, 2019 We reviewed the literature for studies of patients with WD complicated with cancers, and to our knowledge, this is the first report on WD complicated with breast cancer. The patient received chemotherapy even with liver dysfunction, which suggests that patients with WD can be safely treated with paclitaxel chemotherapy under close surveillance.
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, HEOR, Combination therapy: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - May 30, 2019 P2, N=257, Active, not recruiting, Thus, GRP94 may be a key biomarker for the chemotherapeutic response of OS. Recruiting --> Active, not recruiting
- |||||||||| paclitaxel / generics, doxorubicin hydrochloride / generics
Clinical, Journal: Jekyll and Hyde of chemotherapy treatment: method for patient specific dosing of chemotherapy medications. (Pubmed Central) - May 29, 2019 A new method to dose chemotherapy based on a patients albumin will maintain the same effective free drug levels as in patients with normal albumin. This can reduce the severity of chemotherapy side-effects and may: ensure better outcomes for patients since it allows them to complete their course of chemotherapy without interruption, decrease the cost and complications associated with severe side-effects, and will allow for enhanced treatment options.
- |||||||||| Trial completion, Enrollment change, Trial completion date: Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov) - May 29, 2019
P3, N=131, Completed, This can reduce the severity of chemotherapy side-effects and may: ensure better outcomes for patients since it allows them to complete their course of chemotherapy without interruption, decrease the cost and complications associated with severe side-effects, and will allow for enhanced treatment options. Active, not recruiting --> Completed | N=300 --> 131 | Trial completion date: Dec 2018 --> Apr 2019
- |||||||||| Baraclude (entecavir) / BMS
Journal: Long-term Histopathologic Follow-up of a Spherical Embolic Agent; Observation of the Transvascular Migration of HepaSphere. (Pubmed Central) - May 28, 2019 ...A 60-year-old male with chronic hepatitis B was treated with entecavir and seroconversion was obtained...A 1.9 F preshaped microcatheter (ProgreatΣ, Terumo, Japan) was selectively inserted into the A3 and anterior segmental branch, 10 mg of epirubicin was injected into each artery, and the arteries were embolized with 7 mg and 13 mg of HepaSphere loaded with epirubicin, respectively...The largest and smallest HepaSphere diameters were 241.6 ± 52.5 µm and 186.5 ± 41.4 µm, respectively, and deformity was 22.6% ± 13.0 %. All the HepaSpheres detected in the examined pathological specimen were noted to be extravascular.
- |||||||||| Journal: Determination of 16 antineoplastic drugs by capillary electrophoresis with UV detection: applications in quality control. (Pubmed Central) - May 7, 2019
A micellar electrokinetic chromatography (MEKC) method coupled to UV was also developed for the determination of methotrexate, pemetrexed, etoposide, etoposide phosphate, fludarabine phosphate, and 5-fluorouracil...Both methods were validated and trueness values between 99.4% and 101.3% were obtained with repeatability and intermediate precision values of 0.5-1.8% for all drugs. These methods were found appropriate for controlling injectable pharmaceutical formulations containing antineoplastic drugs and successfully applied in quality control.
|